GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Compound class:
Synthetic organic
Comment: Lolamicin is an antibacterial with potential to avoid disruption of the gut microbiota. It has specific activity against Gram-negative pathogenic bacteria, while selectively sparing Gram-negative and Gram-positive commensal strains [2]. Lolamicin is an inhibitor of lipoprotein CDE (LolCDE) [2], a complex found in the membrane of Gram-negative bacteria. It is one of the chemical structures claimed in patent WO2023091873A1 from the University of Illinois [1].
|
|
References |
1. Hergenrother PJ, Muñoz KA. (2023)
Gram-negative specific antibiotics sparing effect on gut microbiome. Patent number: WO2023091873A1. Assignee: The University Of Illinois. Priority date: 19/11/2021. Publication date: 25/05/2023. |
2. Muñoz KA, Ulrich RJ, Vasan AK, Sinclair M, Wen PC, Holmes JR, Lee HY, Hung CC, Fields CJ, Tajkhorshid E et al.. (2024)
A Gram-negative-selective antibiotic that spares the gut microbiome. Nature, 630 (8016): 429-436. [PMID:38811738] |